Year : 2000  |  Volume : 42  |  Issue : 3  |  Page : 302--307

Of the Efficacy and Adverse Effect Profile of Sustained-Release Alprazolam


Chittaranjan Andrade1, Anitha Aswath2, SK Chaturvedi3, R Raguram4, Ajit Bhide5 
1 Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
2 Research Assistant, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
3 Additional Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
4 Additional Professor, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
5 Chief Consultant, Department of Psychiatry, St. Martha's Hospital, Bangalore-560 009, India

Correspondence Address:
Chittaranjan Andrade
Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029
India

In a double-blind, prospective study, 40 patients diagnosed with DSM-IV generalized anxiety disorder and stabilized on alprazolam therapy were randomized to receive the same dose of either conventional or sustained-released alprazolam for two weeks, followed by the other formulation of alprazolam in an identical dose for a further two weeks. Conventional alprazolam was administered thrice daily while the sustained-release formulation was administered once-daily, in the morning. Thirty four patients completed the study. Recruitment into the study was associated with a significant decrease in all measures of illness severity; however, no efficacy differences between the two forms of alprazolam were observed. Adverse effects, specifically insomnia, were reported more with the sustained-release formulation. It is concluded that once-daily sustained-release alprazolam is as effective as the conventional form of the drug, and may be preferable because of a wide range of advantages; in this study, the higher incidence of adverse effects with the sustained-release drug was probably an artefact of the experimental design, which fostered a (nighttime) state of partial drug withdrawal.


How to cite this article:
Andrade C, Aswath A, Chaturvedi S K, Raguram R, Bhide A. Of the Efficacy and Adverse Effect Profile of Sustained-Release Alprazolam.Indian J Psychiatry 2000;42:302-307


How to cite this URL:
Andrade C, Aswath A, Chaturvedi S K, Raguram R, Bhide A. Of the Efficacy and Adverse Effect Profile of Sustained-Release Alprazolam. Indian J Psychiatry [serial online] 2000 [cited 2020 Mar 31 ];42:302-307
Available from: http://www.indianjpsychiatry.org/article.asp?issn=0019-5545;year=2000;volume=42;issue=3;spage=302;epage=307;aulast=Andrade;type=0